Zaire ebolavirus, a member of family Filoviridae is the cause of hemorrhagic fever. Due to lack of appropriate antiviral or vaccine, this disease is very lethal. In this study, we tried to find epitopes for superficial glycoprotein and nucleoprotein of Zaire ebolavirus (that have high antigenicity for MHC I, II and B cells) by using in silico methods and immunoinformatics approach. By using CTLPred, SYFPEITHI and ProPred web applications for MHC class I and SYFPEITHI and ProPred1 web applications for MHC class II, we had been able to find epitopes (peptides) that have the highest score. Also ElliPro, IgPred and DiscoTope web tools had been performed to predict B cells conformational epitopes. Linear epitope prediction for B cell was performed with six methods from IEDB. All of the results that including candidate epitopes for T cells and B cells were reported. It was expected that these peptides could be stimulated immune response and used for designing the multipeptide vaccine against ZEV but these results should be reliable with experimental analysis.
Part of the book: Advances in Ebola Control
Ebola drug discovery continues to be challenging as yet. Proteins of the virus should be targeted at the relevant biologically active site for drug or inhibitor binding to be effective. In this regard, by considering the important role of Ebola virus proteins in the viral mechanisms of this viral disease, the Ebola proteins are selected as our drug targets in this study. The discovery of novel therapeutic molecules or peptides will be highly expensive; therefore, we attempted to identify possible antigens of EBOV proteins by conducting docking-based screening of cell penetrating peptides (CPPs) that have antiviral potential features utilizing Hex software version 8.0.0. The E-value scores obtained in this research were very much higher than the previously reported docking studies. CPPs that possess suitable interaction with the targets would be specified as promising candidates for further in vitro and in vivo examination aimed at developing new drugs for Ebola infection treatment.
Part of the book: Current Perspectives on Viral Disease Outbreaks